Results 201 to 210 of about 28,675 (247)
Some of the next articles are maybe not open access.
Immunologic therapy for relapsing-remitting multiple sclerosis
Current Neurology and Neuroscience Reports, 2001The treatment of relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis, has been revolutionized in recent years. In addition to effective treatment of acute relapses, therapies are now available to prevent relapses, reduce the burden of disease as seen on magnetic resonance imaging, and possibly even slow the course ...
H J, MacLean, M S, Freedman
openaire +2 more sources
Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis
Expert Review of Neurotherapeutics, 2016Despite recent advances in pharmacological management, multiple sclerosis (MS), an autoimmune disease of the central nervous system, remains a leading cause of disability. In relapsing-remitting (RR)MS, neurologists most commonly utilize immunomodulatory or immunosuppressive agents to benefit their patients.
Til, Menge +4 more
openaire +2 more sources
[Relapsing-Remitting Multiple Sclerosis].
Brain and nerve = Shinkei kenkyu no shinpo, 2021Multiple sclerosis (MS) is an immune-mediated inflammatory demyelinating disease of the central nervous system. There are neither diagnostic tests nor markers for MS. Other causes must be excluded thoroughly before an MS diagnosis is considered definitive. The relapsing-remitting type is a major clinical course in MS. Most disease-modifying drugs (DMDs)
Masaaki, Niino, Yusei, Miyazaki
openaire +1 more source
Oral fumarate for relapsing-remitting multiple sclerosis
The Lancet, 2008Udgivelsesdato: 2008/10 ...
Sorensen, P.S., Sellebjerg, F.
openaire +2 more sources
Natalizumab in relapsing-remitting multiple sclerosis
Expert Review of Neurotherapeutics, 2016Natalizumab is the first humanized moclonal antibody indicated in the treatment of relapsing-remitting multiple sclerosis (RRMS). Based on its remarkable efficacy in reducing disease activity and reducing the risk of disability progession in RRMS, and the risk of a serious adverse event (progressive multifocal leukoencephalopathy [PML]), natalizumab ...
openaire +2 more sources
Relapsing-Remitting Multiple Sclerosis
BioDrugs, 2000Multiple sclerosis is now a treatable disease and several immunomodulating therapies exist, but their clinical efficacy is moderate and treatment failure during the course of the disease is an increasing problem. As agents with different targets are available, the question was raised whether combination of these therapies would: be safe;result in ...
M, Mäurer, P, Rieckmann
openaire +2 more sources
Executive functions in relapsing-remitting multiple sclerosis
Applied Neuropsychology: Adult, 2023Some studies suggest that patients with relapsing-remitting multiple sclerosis have problems in the functioning of working memory, and more specifically in executive functions, but the available results are still inconsistent. The aim of the present study was to examine executive functioning in multiple sclerosis using classical and representative ...
M. Rosa Elosúa, Noelia Villadangos
openaire +2 more sources
The efficacy of azathioprine in relapsing ‐ remitting multiple sclerosis
Neurology, 1991We randomized 59 patients with relapsing-remitting multiple sclerosis to receive azathioprine (AZA) 3.0 mg/kg daily or placebo in a double-masked therapeutic trial. Analysis of data for predetermined primary outcome measures demonstrated a significant difference favoring AZA for observed mean exacerbation rate after 2 years of therapy and time to ...
D E, Goodkin +4 more
openaire +2 more sources
Dimethylfumarate in the treatment of relapsing-remitting multiple sclerosis
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2016This review includes results of experimental and clinical studies of dimethyl fumarate, a new oral drug for pathogenetic treatment of multiple sclerosis (MS). The mechanism of action, data from clinical trials, including MRI-results related to tolerability and safety of the drug are reviewed.
E V, Popova, A N, Boyko, E V, Orlova
openaire +2 more sources
Immunomonitoring measures in relapsing-remitting multiple sclerosis
Journal of Neuroimmunology, 2004Forty-five patients with relapsing-remitting multiple sclerosis (MS) were examined to determine intracellular cytokine profiles and the surface phenotype of circulating lymphocytes during active, recovery, and stable stages. Active stage patients were characterized by decreases in CD4(+)IL-4(+) Th2 as well as CD4(+)IFN-gamma(+) Th1 cells, when compared
Makoto, Matsui +4 more
openaire +2 more sources